Business Context and Reporting Period
CI&T Inc., a foreign private issuer based in Brazil, filed this Form 6-K on March 7, 2024. The filing announces a restatement of previously issued financial statements for the year ended December 31, 2022, and the interim periods ended March 31, June 30, and September 30, 2023. The restatement addresses non-cash accounting errors related to deferred income tax accounting for tax-deductible goodwill under IFRS.
Key Financial Metrics and Adjustments
The filing details specific adjustments to historical financial data rather than reporting new operational results for the current period. The primary impacts are as follows:
- Net Income Impact: Net profit for the year ended December 31, 2022, is reduced by approximately R$30.2 million (from R$125.9 million to R$95.7 million). Net income for the nine months ended September 30, 2023, is reduced by approximately R$26.7 million.
- Income Tax Expense: Total income tax expense for 2022 increases by R$30.2 million due to the reclassification of tax-deductible goodwill amortization from a permanent difference to a temporary difference.
- Balance Sheet Reclassifications: Current assets will decrease by R$19.6 million, current liabilities will decrease by R$30.4 million, and non-current liabilities will increase by R$10.8 million.
- Unaffected Metrics: The adjustments are non-cash in nature. Net revenue, operating profit before financial income and tax, Adjusted EBITDA, and cash and cash equivalents remain unchanged.
Material Changes Versus Prior Period
The material change is the withdrawal of reliance on previously filed financial statements for the "Non-Reliance Periods" (2022 annual and 2023 interim periods). The errors stemmed from:
- Incorrectly treating tax-deductible goodwill amortization as a permanent difference rather than a temporary difference, understating income tax expense by R$40.5 million in 2022 and R$30.9 million in the first nine months of 2023.
- Incorrectly treating amortization of identifiable intangible assets from the Dextra acquisition as non-deductible, overstating income tax expense by R$10.3 million in 2022 and R$4.1 million in the first nine months of 2023.
Guidance, Outlook, and Risks
Management Commentary and Plans: The Company intends to file restated financial statements for 2022 alongside the audited 2023 statements in its upcoming Form 20-F, expected before April 30, 2024. A separate Form 6-K detailing the impact on 2023 interim periods will also be filed. The Company does not plan to amend the 2022 Form 20-F.
Risks and Contingencies: The restatement is attributed to a material weakness in internal controls. Forward-looking statements are subject to risks including the completion of the audit process, geopolitical conflicts (Ukraine/Russia, Israel/Hamas), competition, and integration of recent acquisitions.
Investor Verification Checklist
- Verify the upcoming Form 20-F filing (due before April 30, 2024) for the final restated 2022 and 2023 financial statements.
- Monitor for the subsequent Form 6-K detailing the specific restatement impacts on the 2023 interim periods (Q1, Q2, Q3).
- Review the Company's disclosure regarding the remediation of the identified material weakness in internal controls.
- Confirm that cash flow and Adjusted EBITDA metrics remain consistent with previously reported figures despite the net income reduction.